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Background: The evolution of mutations in the BCR-ABL1 fusion gene transcript renders CML patients resistant to
tyrosine kinase inhibitor (TKI) based therapy. Thus screening for BCR-ABL1 mutations is recommended particularly in
patients experiencing poor response to treatment. Herein we describe a novel approach for the detection and
surveillance of BCR-ABL1 mutations in CML patients.
Methods: To detect mutations in the BCR-ABL1 transcript we developed an assay based on the Pacific Biosciences
(PacBio) sequencing technology, which allows for single-molecule long-read sequencing of BCR-ABL1 fusion transcript
molecules. Samples from six patients with poor response to therapy were analyzed both at diagnosis and follow-up.
cDNA was generated from total RNA and a 1,6 kb fragment encompassing the BCR-ABL1 transcript was amplified using
long range PCR. To estimate the sensitivity of the assay, a serial dilution experiment was performed.
Results: Over 10,000 full-length BCR-ABL1 sequences were obtained for all samples studied. Through the serial dilution
analysis, mutations in CML patient samples could be detected down to a level of at least 1%. Notably, the assay
was determined to be sufficiently sensitive even in patients harboring a low abundance of BCR-ABL1 levels. The
PacBio sequencing successfully identified all mutations seen by standard methods. Importantly, we identified
several mutations that escaped detection by the clinical routine analysis. Resistance mutations were found in all
but one of the patients. Due to the long reads afforded by PacBio sequencing, compound mutations present in
the same molecule were readily distinguished from independent alterations arising in different molecules. Moreover,
several transcript isoforms of the BCR-ABL1 transcript were identified in two of the CML patients. Finally, our assay
allowed for a quick turn around time allowing samples to be reported upon within 2 days.
Conclusions: In summary the PacBio sequencing assay can be applied to detect BCR-ABL1 resistance mutations in
both diagnostic and follow-up CML patient samples using a simple protocol applicable to routine diagnosis. The
method besides its sensitivity, gives a complete view of the clonal distribution of mutations, which is of importance
when making therapy decisions.Background
Treatment of chronic myeloid leukemia (CML) has ad-
vanced with the introduction of tyrosine kinase inhibi-
tors (TKI) that target the BCR-ABL1 fusion protein such
as imatinib, and furthermore with second line inhibitors
such as dasatinib, nilotinib, bosutinib and ponatinib. To* Correspondence: lucia.cavelier@igp.uu.se
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unless otherwise stated.measure the effect of TKI therapy, real-time quantitative
PCR (RQ-PCR) of the BCR-ABL1 fusion transcript is
routinely performed and transcript levels are followed
longitudinally for each patient. However, in case of lim-
ited TKI response or of progression to accelerated phase
or blast crisis, mutational analysis of the ABL1 kinase
domain should be performed, as stated by the ELN
(European Leukemia Net) recommendations [1], since
evolution of such mutations may lead to poor response
to TKIs. One mutation of particular importance for clinical
investigations is the multi-resistant substitution T315I,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing site. Furthermore, rare mutations within the regulatory
domain of ABL1 have also been reported to lead to TKI re-
sistance in patients without kinase domain mutations [2].
A further concern is the presence of concurrent BCR-
ABL1 mutations, which may also hamper successful ther-
apy [3-5]. Ideally, mutations in both regulatory and kinase
domains as well as co-existing mutations should therefore
be detected as early as possible, prior to an expansion of
resistant clones. In addition to point mutations, the BCR-
ABL1 protein can be affected by alterations in splicing
where whole exons, or smaller parts of exons, are included
or skipped from the main transcript [6,7]. The clinical sig-
nificance of splice isoforms remains to be elucidated,
mainly because their detection has until recently required
time consuming cloning steps prior to sequencing.
Today, various assays including Sanger sequencing and
quantitative RT-PCR are routinely applied for BCR-ABL1
mutation detection. While Sanger sequencing has limited
sensitivity, real time reverse transcription PCR requires
mutation specific panels with separate standard curves
and variable sensitivity. A further limitation is that these
assays can typically not resolve the patterns of co-existing
mutations. With the introduction of massively parallel se-
quencing (MPS) technologies it is now possible to study
these mutations at an entirely new level of resolution. In
recent studies performed on the Roche 454 system, BCR-
ABL1 mutations were detected at a higher sensitivity as
compared to Sanger sequencing [8,9]. However, although
the 454 system produces longer sequences than most
other instruments, these still cannot span the complete
transcript. Thus, MPS studies have until now mainly been
based on sequencing of smaller fragments of BCR-ABL1,
often amplified in two successive rounds using a nested
PCR approach. This strategy not only limits the analysis
to a portion of the transcript but it is likely to introduce a
bias in the resulting mutation frequencies.
Here we present for the first time an assay to directly
investigate the entire 1,578 bp BCR-ABL1 major fusion
transcript, amplified from a single PCR reaction and
sequencing on the Pacific Biosciences (PacBio) RSII
system. When comparing available MPS platforms, the
PacBio instrument is particularly attractive for BCR-ABL1
analysis. In addition to enabling a rapid workflow at a rela-
tively low cost, the PacBio system produces reads suffi-
ciently long to span across a full length BCR-ABL1
molecule. This allows for an immediate detection of
compound mutations and splice isoforms.
Methods
Patient samples
Six patients diagnosed with CML at Uppsala University
Hospital, all receiving imatinib as first line treatment
were included in this study. All six patients showedlimited or no molecular response to TKI treatment. Two
of the patients were included in a ponatinib study
(PACE, study nr AP24534-10-201, phase 2 clinical trial,
Ariad Pharmaceuticals, MA, USA). Samples at diagnosis,
and following TKI therapy were tested. For a complete
list of all patient samples sequenced in this study, see
Table 1. The clinical characteristics of each patient are
given in further detail in the results section.
Ethics statement
This study was performed in accordance with the Dec-
laration of Helsinki. The Ethical Committee at Uppsala
University, Dnr 00–623, approved this study. Written
informed consent was obtained from the patients.
RNA extraction and cDNA synthesis
RNA was extracted from peripheral blood or bone mar-
row samples using a TRIzol®, (Thermoscientific, MA,
USA) standard protocol and quantified by the nanodrop
2000 instrument (Thermoscientific, MA, USA). cDNA
was synthesized using the SMARTer™ PCR cDNA syn-
thesis kit (ClonTech, CA, USA), using 1000 ng total
RNA.
Dilution series of BCR-ABL1 samples
Using a quantitative real time reverse transcription PCR
assay, total BCR-ABL1 p210 transcripts were quantified
in the 49 month post diagnosis sample for patient three
(P3) and a wild type sample at diagnosis. The two sam-
ples where then diluted to contain the same amount of
BCR-ABL1 copies/microliter. The P3 sample was then
serially diluted into the sample wild type at varying
amounts 50%, 10%, 1% and 0.5%.
Library preparation and PacBio sequencing
Long range PCR amplification of the BCR-ABL1 p210
transcript was performed using the Clontech Advantage
PCR kit (Clontech, CA, USA). Using BCR-ABL1 specific
primers (BCR exon 12, forward 5’- tga cca act cgt gtg tga
aac tc – 3’ and ABL1 exon9/10, reverse 5’ - tcc act tcg
tct gag ata ctg gat t - 3’) a 1578 bp cDNA amplicon ran-
ging from exon 12 (including e13 and e14 breakpoint
variants) in BCR to exon 9 in ABL1 was obtained. The
cDNA reaction was diluted to 50 μl using TE buffer.
5 μl of diluted cDNA were used in a 50 μl PCR reaction,
following the manufacturers instructions. Samples were
placed into a preheated 95°C thermocycler and cycled as
follows; initial denaturation for 1 minute at 95°C followed
by 30 cycles of 15 seconds at 95°C, 30 seconds at 61°C
and 3 minutes at 68°C. Following amplification, amplicon
size was confirmed using the bioanalyser 12000 kit
(Agilent, CA, USA) and the concentration confirmed
by Qubit assay (Life Technologies, CA, USA).
Table 1 Characteristics of the patient samples included in this study
Age/sex Sokal
score






Patient 1 43/M high risk 46,XY,t(9;22)(q34;q11)[20] CP CML 0 37432 wildtype ND
ND CP CML 7 32703 T315I (3.9%) wildtype
ND CP CML 9 30251 T315I (53,5%) ND
Patient 2 70/M high risk 46,XY,t(9;22)(q34;q11)[25] CP CML 0 23089 wildtype ND
46,XY,t(9;22)(q34;q11)[19]/ 6 27633 wildtype ND
46,XY,t(9;22)(q34;q11)[4]/46,XY,
idem,del(11)(q14)[16]
AP CML 43 34467 wildtype wildtype
ND but later sample shows 46,
XY,t(9;22)(q34;q11)del(11)(q14)[20]
64 41963 T315I (98%) T315I
Patient 3 65/M high risk 46,XY,t(9;22)(q34;q11)[25] CP CML 0 35377 wildtype ND




AP CML 49 39685 T315I (88,9%), F359C (4,2%) T315I
46,XY,t(9;22)(q34;q11)[3]/46,XY,
del(5q)[6]/46,XY[10]
AP CML 55 42642 T315I (94,8%), F359C (2,2%),
D276G (1,8%), H396R (1%)
T315I
Patient 4 61/F high risk 46,XX,t(9;22)(q34;q11)[25] CP AML 0 36658 wildtype ND
46,XX[20] CP CML 111 41922 F359I (83,1%), T315I (13,5%) F359I,
T315I
Patient 5 66/M ND CP CML 0 24062 wildtype ND
46,XY,del(6)(q2?1;q2?3),-7,t(9;22)
(q34;q11)[20]
Blast crisis 4 28446 Y253H (94,8%), E255V (1,8%) Y253H
Patient 6 65/M 46,XY,t(9;22)(q34;q11)[20] CP CML 0 32982 wildtype ND
46,XY,t(9;22)(q34;q11)[11]/ CP CML 7 29221 4 isoforms wildtype
46,XY[20] CP CML 13 34726 3 isoforms ND
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Biosciences 1.0 template preparation kit according to the
manufacturer’s instructions. SMRTbells™ were constructed
and sequenced following the recommended pacific biosci-
ences 2kb template preparation protocol. In brief, cDNA
amplicons (300–750 ngs) underwent end-repair and
adaptor ligation processes to generate SMRTbell™ librar-
ies for circular consensus sequencing. Libraries were then
subjected to exo treatment and Ampure bead wash proce-
dures for clean up. SMRTbell™ libraries were quantified
using the Qubit assay and library size was confirmed using
the bioanalyser 12000 kit. Following SMRTbell™ construc-
tion, v2 primers and P4 polymerase were annealed and en-
zyme bound complexes attached to magnetic beads for
loading. Each SMRTbell™ amplicon library was loaded on
to one SMRT cell and sequenced on the PacBio RS II in-
strument using C2 chemistry and a 120 minute movie
time.
PacBio data analysis and mutation detection
Detection of mutations in the PacBio data was performed
using the ‘Minor and Compound Variants’ plug-in avail-
able in v2.0.1 of the PacBio SMRTAnalysis Portal. Custom
R scripts were used to study the mutational compositionin patients carrying several mutations. This was done by
looping through all circular consensus (CCS) reads and
recording the mutational composition in each individual
read. For a read to be present in the analysis of compound
mutations, 20 bases in a window surrounding each muta-
tion were required to match perfectly to the BCR-ABL1
p210 transcript reference sequence. In this way only reads
with relatively high quality were used, thereby reducing
the effects of sequencing errors.
Detection of BCR-ABL1 isoforms
BCR-ABL1 splice isoforms were identified from full-length
CCS reads spanning the length of the entire transcript.
For a splice isoform to be reported, we required at least
two independent CCS reads to contain identical nucleo-
tide sequences over the entire length of the transcript.
Results
This study shows the applicability of PacBio sequencing to
detect BCR-ABL1 mutations in CML patients with poor
molecular response to treatment. As a proof of concept
we have analyzed patient samples previously analyzed by
standard routine methods and all but one were positive
for TKI-resistance mutations. Besides confirming all
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mutations. Most importantly, we could determine the
clonal distribution of mutations, thereby bypassing the
need of cloning experiments. We could establish if
mutations were present in the same (compound) or in
different molecules (independent), which is clinically
relevant for therapy decision-making. Furthermore we
could simultaneously detect transcripts isoforms.
Sequencing and sensitivity of the assay
We designed a simple workflow with a single step PCR-
amplification aimed comprising a 1,6 kb fragment of the
fusion transcript and excluding the wild-type ABL1. This
fragment was then sequenced using the PacBio sequen-
cing protocol. We estimate that the whole process from
cDNA synthesis to PacBio sequencing and analysis can
be performed within 2–3 days (see Figure 1A). Results
from one CML patient (patient 3) show that sequencing
on a single PacBio SMRT cell generated a uniform mapped
read coverage of about 10,000X across the entire length of
the BCR-ABL1 amplicon (Figure 1B). In order to evaluate
the sensitivity and specificity of our assay, serial dilutions
from patient P3 harboring T315I and F359C ABL1 muta-
tions were diluted into wild type BCR-ABL1 and analyzed.
Our results show that the T315I mutation could be de-
tected down to an expected frequency of 1%, while F359CFigure 1 Overview and evaluation of BCR-ABL1 mutation detection us
Total RNA was used to generate a 1578 bp long BCR-ABL1 fusion transcript
the resulting library was sequenced on a PacBio SMRT cell. The data analys
well as the different clones present in the sample. B) Alignment of reads to
CML sample (patient P3,49 months) produced from one SMRT cell on the P
of about 10,000X over the entire reference sequence. The red vertical line i
reads. The mutation F359C was also detected in this sample at a frequency
experiment of the CML sample in panel B) (P3, 49 m). The leftmost bars sh
sample. To the right are observed mutation frequencies for a dilution serie
0.5%. The expected frequencies of T315I and F359C are shown in red and
not detected by the PacBio sequencing.was found down to 0.5% (Figure 1C). This is in concord-
ance with recent MPS studies that detected mutations
down to 1% [4,8]. Importantly, not a single mutation other
than T315I and F359C were found in any of the 5 samples
in the dilution series, indicating a 0% false positive rate and
thus a perfect specificity for these samples. The low false
positive rate is likely explained by the random distribution
of sequencing errors inherent to the PacBio technology
[10,11], which results in highly accurate base calls for mol-
ecules that are sequenced at high coverage.
We further analyzed samples taken at the time of diag-
nosis as well as at later time points following TKI treat-
ment for six patients with limited or no molecular
response to TKI treatment (see Table 1). All together, 22
samples were sequenced generating an average of 32,000
CCS reads per sample (Table 1). We identified a total of
13 mutations distributed over the residues Y253H,
E255V, D276G,T315I, F359I, F359C and H396R (Figure 2).
All mutations have previously been implicated in resist-
ance to one or more TKIs. Besides, all of these positions,
except the D276, are among the 12 key positions previ-
ously reported in compound mutants [5]. In all six pa-
tients, the PacBio system successfully confirmed all
mutations previously detected by Sanger sequencing.
Moreover, we identified 5 mutations present at low fre-
quency (below 5%) that previously failed detectioning the PacBio sequencing. A) Schematic overview of the workflow.
cDNA amplicon. PacBio adaptors were ligated to the amplicon and
is detected BCR-ABL1 mutations down to a frequency of at least 1%, as
the BCR-ABL1 reference sequence. The grey area shows reads for a
acBio RSII instrument. The sequencing generates a uniform coverage
ndicates the presence of a T315I mutation, present in 88.9% of the
of 4.2% and can be seen as a faint vertical line. C) Results of a dilution
ow mutation rates of T315I (red) and F359C (blue) for the undiluted
s where the expected T315I frequency reached 50%, 10%, 1% and
blue letters, respectively. Positions marked with ‘X’ indicate mutations
Figure 2 BCR-ABL1 mutations and their composition in patient samples. Overview of BCR-ABL1 mutations detected in five CML patients (P1-P5)
at the time of diagnosis and at subsequent follow-up examinations following TKI treatment. Samples taken at the time of diagnosis are labeled ‘Diag’.
The follow-up samples are labeled with the number of months after diagnosis. The numbers next to the colored bars show the frequencies of all
mutations observed by PacBio sequencing. Asterisks (*) indicate mutations that failed to be detected by Sanger sequencing.
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rying a single mutation, three patients carried more
than one mutation and for the last patient no point
mutations were detected. The results for the individual
patients are described in more detail below.
Patients with the T315I as a single mutation
We detected only the T315I mutation in two patients
(1 and 2) (Figure 3). As shown in Figure 3A, patient 1
was diagnosed with chronic phase CP-CML. No sig-
nificant molecular remission was seen after 15 months
of imatinib therapy and the patient underwent allogeneic
stem cell transplantation (SCT). At present the patient is
in complete molecular remission. It is noteworthy that, in
this case the T315I was detected with Sanger sequencing
13 months after diagnosis while a small clone (4%) could
be detected in a sample taken four months earlier using
the PacBio sequencing.
Patient 2 shown in Figure 3B was diagnosed with
CP-CML with no significant molecular response fol-
lowing imatinib therapy. After 18 months, the patient
received dasatinib followed by switch to nilotinib after
four months, and then to hydroxyurea after furtherthree months. The patient progressed to AP-CML dur-
ing hydroxyurea treatment and at 38 months after
diagnosis the T315I mutation could be detected by
routine analysis using allele specific qPCR and Sanger
sequencing. Notably, at this point a Philadelphia posi-
tive clone with del (11q) was found in the karyotype
analysis. After few months on hydroxyurea the patient
lost the T315I mutated clone and the PacBio analysis
did not detect the T315I or any other mutation (Figure 3B).
These results were in accordance with the Sanger sequen-
cing and qPCR analysis. The patient then received ponati-
nib treatment, outside the PACE study. After an initial
molecular response and following twelve months of pona-
tinib therapy, molecular relapse occurred. As measured by
the PacBio sequencing, the T315I mutation reached
98% at this point but no other mutations were detected
(Figure 3B). We can thus speculate that in this patient
BCR-ABL1-independent factors explain TKI resistance.
The patient was switched back to imatinib therapy due
to severe cardiovascular side effects from ponatinib
and rising T315I values. The latest karyotype analysis
showed Philadelphia positive cells only, with all cells
containing the previously found del (11q).
Figure 3 Overview of treatments and PacBio results for patients with single mutations. A) Results for patient 1. The BCR-ABL1 IS% values
measured by routine quantitative RT-PCR are shown in open circles. The sensitivity of this assay was measured for the BGUS reference gene and
depicted by gray squares. The samples that were analyzed by PacBio sequencing are indicated by black arrows and their mutation composition
showed in the circle plot diagrams above each time point. Vertical lines indicate the treatment periods. HU (Hydroxyurea). B) Results for patient 2.
The T315I mutation was detected after nilotinib treatment, as indicated by the red cross. The mutation was detected at this time point using our
allele specific quantitative PCR used in routine analysis.
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More than one mutation was present in three of the pa-
tients (3,4 and 5) (Figure 2). As shown in Figure 4A Pa-
tient 3 was diagnosed with CP-CML with no significant
molecular response to imatinib. Due to the occurrence
of T315I mutation the therapy was switched to hydroxy-
urea to avoid further selection of the T315I positive
clone. The patient progressed to accelerated phase (AP)
after 9 months of hydroxyurea therapy. The patient wasthen included in the PACE clinical trial. After a few
months of ponatinib treatment the T315I mutation was
still detected and with the occurrence of another muta-
tion F359C. The PacBio sequence analysis showed that
the mutations were localized in different molecules (see
Figure 4B). After additional months of treatment two small
T315I positive clones emerged, carrying the D276G (2%)
and the H396R (1%) respectively, while the F359C positive
clone was reduced by half. Interestingly, a Philadelphia
Figure 4 Overview of treatments and PacBio results for patient 3. A) The BCR-ABL1 IS% values measured by routine quantitative RT-PCR are
shown in open circles. The sensitivity of this assay was measured for the BGUS reference gene and depicted by gray squares. As indicated by the
red cross, the T315I mutation was detected after eleven months of imatinib treatment. The mutation was detected at this time point using our
allele specific quantitative PCR used in routine analysis. The samples that were analyzed by PacBio sequencing are indicated by black arrows
and their mutation composition showed in the circle plot diagrams. Vertical lines indicate the treatment periods. HU (Hydroxyurea). B) This
panel shows the mutational composition in the BCR-ABL1 transcript for the 49 m and 55 m follow-up samples. Horizontal lines gives a schematic
representation of high-quality PacBio reads that were used for examining the mutational composition. At 49 m, 91.8% of the reads carried T315I mutation.
4.2% of the reads showed the presence of F359C and 3.9% of the reads contained none of the mutations. At 55 m, two new clones appeared, one
containing D276G and T315I (2.0% of the reads) and one containing T315I and H396R (1.1% of the reads).
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emerged 6 months after ponatinib study inclusion and has
over time become the prevalent clone in this patient.
Patient 4 (Figure 5A) was diagnosed with CP-CML
and initially treated with hydroxyurea and interferon
followed by imatinib therapy for 36 months with minor
molecular response, due to the F359I and F359V muta-
tions detected at this point by Sanger sequencing.
Therapy change to dasatinib resulted in a molecular
response, however followed by a later increase in BCR-
ABL1 transcripts and emergence of the T315I muta-
tion. The treatment was changed to hydroxyurea plus
dasatinib, followed by two short periods with nilotinib
and ponatinib (PACE study) treatments respectively.
Due to severe side effects of ponatinib, the patient wasswitched back to the previously used combination of
hydroxurea and dasatinib. At present the patient shows
only minor molecular response. The PacBio analysis
was performed during this last treatment period and
showed the F359I (86%) and the T315I (14%) muta-
tions in separate clones. Further analysis is required to
evaluate the future clonal evolution and treatment re-
sponse to the present therapy.
Patient 5 was diagnosed in late CP-CML. Therapy chan-
ged from imatinib to nilotinib four months post diagnosis
(Figure 5B). After one month on nilotinib therapy, the
patient developed Y253H (95%) and E255V (2%) muta-
tions and went into a blast crisis. The patient then received
chemotherapy (following the “EWALL” protocol) and
dasatinib. Allogeneic SCT was performed but four months
Figure 5 Overview of treatments and PacBio results for patients 4 and 5. A) Results for patient 4. The BCR-ABL1 IS% values measured by
routine quantitative RT-PCR are shown in open circles. The sensitivity of this assay was measured for the BGUS reference gene and depicted by
gray squares. As indicated by the red cross, the T315I mutation was detected after 58 months of dasatinib treatment. The mutation was detected
at this time point using our allele specific quantitative PCR used in routine analysis. The samples that were analyzed by PacBio sequencing are
indicated by black arrows and their mutation composition showed in the circle plot diagrams. Vertical lines indicate the treatment periods.
HU (Hydroxyurea). B) Results for patient 5. Measurements shown were made as in A. AlloSCT: allogeneic stem cell transplantation. DLI: donor
lymphocyte infusion.
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ABL1 values. Interestingly at this point the patient showed
none of the previously seen point mutations but instead we
could detect BCR-ABL1 transcript isoforms. The patient
then received donor lymphocyte infusion and dasatinib to
later go under ponatinib treatment. The patient is at
present in MR 4,5 continuing the ponatinib therapy. Ac-
cording to the sequencing results these two mutations
resided in separate molecules. The Y253 and E255Vmutations are well known P-loop mutations causing resist-
ance to imatinib and nilotinib while sensitive to dasatinib
when either found individually or in the same molecule
[5]. However, the compound mutant shows resistance to
ponatinib, while the two mutants are individually sensitive.
Patients with transcripts isoforms
Besides establishing the clonality of mutations, our method
could also identify transcript isoforms in patients 5 and 6.
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forms when losing molecular response after allogeneic
stem cell transplantation (Figure 5). Patient 6 was diag-
nosed with CP-KML and showed slow molecular response
after 18 months receiving imatinib (Figure 6A). The patient
responded better to nilotinib therapy and at present theFigure 6 Overview of treatments and PacBio results for patient 6. A)
shown in open circles. The sensitivity of this assay was measured for the BG
were analyzed by PacBio sequencing are indicated by black arrows. The ve
isoforms in patient 6. At 7 months post diagnosis four different splice isofo
(WT) BCR-ABL1 transcript isoform, i.e. identical to the reference sequence us
contained insertions of entire exons, of lengths 35 bp and 154 bp, respecti
13 months post diagnosis the WT isoform was present in 54% of the mole
and 9 in ABL1 was present in the other two isoforms.patient has reached MMR. In this case several splice iso-
forms were present both at 7 and 13 months post diag-
nosis (Figure 6B). No less than four different isoforms
were identified in the sample taken 7 months after
diagnosis with two lower frequency isoforms detected
besides the WT transcript and 35INS. One isoform had aBCR-ABL1 IS% values measured by routine quantitative RT-PCR are
US reference gene and depicted by gray squares. The samples that
rtical line indicates the treatment period. B) This panel shows BCR-ABL1
rms were identified. The most common isoform was the ‘wild type’
ed for mapping, present in 80% of the molecules. Two other isoforms
vely and one contained a partial deletion of exon 7 of ABL1. At
cules whereas isoforms containing the 35 bp insertion between exon 8
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ABL1, leading to a truncated protein (present in 6% of
transcripts), while the other isoform had a deletion of 24
amino acids in exon 7 of ABL1 (present in 2% of tran-
scripts). Notably, the frequency of the wild type BCR-ABL1
wild type isoform decreased from 80% to 54% between the
two time points (6C), while splice isoforms carrying an in-
sertion of an additional 35 bases (35INS) between exons 8
and 9 in ABL1 increased in frequency. This exact 35 bp in-
sertion has been reported previously in patients undergo-
ing kinase inhibitor therapy [12].
Discussion
Our results show that mutations can be detected at a
level of ~1% in a background of wild type BCR-ABL1
making it a useful tool for screening of both high and
low level kinase domain mutations. Further, it provides
information on the clonal distribution of mutations as
well as BCR-ABL1 isoforms in a single assay. This fea-
ture is of major clinical relevance as compound mutations
show different resistance profiles compared to individual
mutants [5]. Standard Sanger sequencing methods rou-
tinely used in diagnostic laboratories are unable to distin-
guish between independent or compound mutations. Until
now, this information has only been available through time
consuming cloning experiments [5], underlining the poten-
tial clinical utility of our assay.
Although recent reports showing MPS-approaches are
emerging [8,9], its usefulness in establishing the clonality
of mutations has recently been debated. In a recent re-
port, Parker et al. [13] showed that compound mutations
detected by MPS technologies might actually be artifacts
due to PCR-mediated recombination. However, our assay
has a somewhat different setup compared to previous
studies. Instead of performing a two round nested PCR, as
is required for shorter read technologies, the fusion
transcripts were amplified in one single round. This
could potentially reduce the rate of PCR recombin-
ation. We were able to evaluate the degree of in vitro arti-
facts in our experiments. For example, in the 49-month
sample from patient 3, 91.2% of the reads contained
only T315I and 4.2% of the reads contained only
F359C (see Figure 4B). In the same sample 0.1% of
reads show the presence of both T315I and F359C.
These results suggest that the recombination rate in
this particular case is very low, well below the fre-
quency of the individual clones. However, since the
rate of chimeric reads can be influenced by the experi-
mental conditions and may vary between samples, a
more thorough investigation would be required to validate
the PCR recombination rate under different circumstances.
On the practical level, the PacBio assay allows for a sim-
ple, efficient and streamlined workflow conducive to clin-
ical routine. Our laboratory workflow provides a quickturnaround time of approximately two days, encompass-
ing all steps from RNA isolation to report generation. A
simple library preparation procedure, rapid sequencing
and straight forward bioinformatics analysis enable this ef-
ficient workflow. The library preparation is performed
during one day and the sequencing run takes approxi-
mately 2–3 hours per sample. Under the current set up,
PacBio sequencing is more expensive compared to the
more traditional Sanger sequencing and RQ-PCR based
assays. However, the cost for sequencing of small target
regions such as the BCR-ABL1 transcript is comparable to
that of other available MPS technologies. In the present
study, we obtained 10,000X coverage of BCR-ABL1 for
each of the samples. In light of this rather extensive cover-
age, it is likely that a similar sensitivity for mutation
detection could to be obtained when utilizing a reduced
coverage, thus opening up the possibility of barcoding of
two or more samples on one SMRT cell. Further, due to
the continuous improvements of the PacBio system in
terms of quality, read length and throughput, the potential
for multiplexing is likely to increase, thus leading to sub-
stantial reductions in experimental cost.
This study presents a proof of principle for detection
of BCR-ABL1 mutations and our results are based on
just a handful of patients, limiting the generality of our
conclusions. Nevertheless the analysis of individual pa-
tient samples illustrates important aspects and strengths
of our approach. One main advantage is the sensitivity
of the assay, as illustrated in one of the patients (patient 1)
where we could detect the T315I mutation four months
earlier than detected by Sanger sequencing. These results
indicate that an NGS-screen could be informative when
performed at earlier time points, possibly in patients with
no or limited responses to TKI therapy already at the
three months control. Further studies are needed to spe-
cifically address this question.
The sensitivity of the method can also be instrumental
in excluding other BCR-ABL1 mutations as responsible
factors for the observed TKI resistance. For example, in
patient 2, we could only detect the T315I and despite an
initial molecular response to ponatinib, the patient re-
mains with a minor molecular response. Thus in this
case BCR-ABL1-independent factors might explain the
failed therapy. This information is of particular importance
when looking for alternative TKI-resistance pathways.
The ability to discern between independent and com-
pound mutations is a major advantage of this assay. For
example, patient 3 carried both the T315I and F359C
mutations, but present in independent clones. A recent
study has shown that the compound mutation F359C
and T315I is associated with in vitro profiles implicating
mutant pairing of these two positions in moderate and
high-level resistance to ponatinib and rebastinib, re-
spectively [5], while the individual mutants are instead
Cavelier et al. BMC Cancer  (2015) 15:45 Page 11 of 12sensitive to these substances. Thus, we can speculate
that the molecular response observed in this case upon
ponatinib treatment, can be explained by the fact that
these mutations are located in different molecules in
this patient. In contrast, the T315I positive clone (84%)
acquired independently two extra mutations (D276G
and H396R) upon ponatinib treatment. These low fre-
quency compound sub clones did not seem to impede
the molecular response (MR5) attained after 3 years of
treatment. The results are somehow conflicting with
recent results showing that the compound mutant
H396R/T315I has an intermediate to high resistance
in vitro profile with an IC50 for ponatinib of 90.8 ± 24.7
nM compared to an IC50 of 20.1 ± 3.5 (H396R) and
29.1 ± 7.8 nM (T315I) for the individual mutants [5].
However, in vitro sensitivity does not necessarily al-
ways correlate with the clinical response to treatment.
Similarly, patient 5, harboring the non-compound Y253H/
E255V mutations, would clearly benefit today from sensitive
examination of the clonal composition of these two
mutations prior to therapy decisions because of the
high ponatinib-resistance of the Y253H/E255V com-
pound mutant [5]. The fact that in this patient the mu-
tations occur in different molecules would remain
indiscernible by routine Sanger sequencing.
Another advantage of our approach is that as we amp-
lify and sequence almost the entire BCR-ABL1 p210
transcript we are able to identify transcript isoforms. We
identified elevated levels of transcripts isoforms in two
of the patients. Among the variants that we detected,
35INS is best studied in the literature. Some studies have
described 35INS as a possible mechanism of imatinib re-
sistance [14,15], while biochemical data from a separate
study shows that it does not contribute to TKI resistance
in vitro [16]. Although there is at present no basis for
taking 35INS into consideration for treatment decisions,
these conflicting reports highlight the need for routine
screening in CML patients in order to gain more know-
ledge. Our results suggest that the PacBio assay can be
used for screening of 35INS as well as other splice iso-
forms down to a frequency of at least 5%. Furthermore,
it enables simultaneous detection of multiple different
alternative isoforms present in a single sample. These re-
sults corroborate previous findings that propose alterna-
tive splicing as a common mechanism among CML
patients undergoing TKI treatment [14,17]. However, to
clarify the role of transcript isoforms in drug resistance
and response a larger number of samples should have to
be analyzed and our approach might simplify this kind
of analysis.
Although this study is focused on BCR-ABL1 the same
method can be readily applied to the analysis of other
cancer-associated fusion transcripts, providing not only
information on the clonal distribution of mutations butalso on isoform frequencies. Isoform analysis is to this
date not performed routinely on CML patient samples
and therefore the knowledge on their impact on disease
progression and treatment efficiency is very limited.Conclusions
This study presents an NGS method for the detection of
BCR-ABL1 mutations associated with TKI-resistance. We
show a simple workflow with a rapid turn around time.
The strengths of this method are its sensitivity, enabling
early detection of resistance mutations, and its capability
to discern between individual and compound mutations.
Thus we believe that this assay can potentially be intro-
duced into clinical practice to guide therapeutic decisions
for TKI resistant patients, provided thorough validation in
a larger number of samples.
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